Drug Table - Alkylating Agents Flashcards

1
Q

Alkylating Agents Mechanism

A

Produce strong electrophiles through
carbonium or ethyleneimonium ion
intermediates, which covalently bond via
alkylation of nucleophilic moieties in DNA
(mostly N7 position of guanine); Cell Cycle
Non-Specific (CCNS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Alkylating Agents Important Side Effects

A

Bone marrow, mucosal toxicity,
nausea and vomiting, toxic effects
on reproductive systems,
increased leukemia risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Alkylating Agents Miscellaneous

A
Resistance may occur due to:
decreased permeability or uptake;
increased rates of catabolism;
enhanced DNA repair; increased
glutathione production (inactivates
via conjugation)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

List 11 Alkylating Agents

A
Mechlorethamine (Mustargen)
Cyclophosphamide (Cytoxan)
Ifosfamide (Ifex)
Carmustine (Gliadel)
Lomustine (Ceenu)
Dacarbazine (DTIC)
Procarbazine (Matulane)
Temozolomide (Temodar)
Cisplatin (Platinol)
Carboplatin (Paraplatin)
Oxaliplatin (Eloxatin)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Mechlorethamine class

A

(Mustargen)

Nitrogen mustard

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mechlorethamine mechanism

A

Alkylating agent; spontaneous conversion to active metabolites in body fluids or
enzymatically converted in liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mechlorethamine Therapeutics

A

Hodgkin’s disease, topically for treatment of cutaneous T-cell lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mechlorethamine “Other” side effects

A

Severe nausea and vomiting,
myelosuppression (leucopenia,
thrombocytopenia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mechlorethamine Misc

A

Don’t use much anymore due to sterility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cyclophosphamide
(Cytoxan)
Class

A

Nitrogen mustard

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cyclophosphamide
(Cytoxan)
Mechanism

A

Alkylating agent; conversion by hepatic cytochrome P450 to active metabolite phosphoramide mustard

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Cyclophosphamide
(Cytoxan)
Therapeutics

A

Most widely used alkylating agent (broad clinical spectrum); singly or in
combination for ALL, CLL, non-Hodgkin’s lymphoma, and breast, lung, and ovarian cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cyclophosphamide
(Cytoxan)
Important Side Effects

A
Hemorrhagic cystitis (bladder
irritation) due to acrolein (toxic
drug metabolite); adequate
hydration and administration of
MESNA (2-mercaptoethane
sulfonate) minimizes problem
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cyclophosphamide
(Cytoxan)
“Other” Side Effects

A

Nausea, vomiting,

myelosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cyclophosphamide
(Cytoxan)
Miscellaneous

A

Relatively long plasma half-life (7-15 hrs); taken orally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Difference between Ifosfamide and Cyclophosphamide

A

Therapeutics
Ifos is used for Sarcoma and testicular cancer
Cyclophosphamide is the most widely used

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Carmustine (Gliadel)
Lomustine (Ceenu)
Class

A

Nitrosoureas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Carmustine (Gliadel)
Lomustine (Ceenu)
Mechanism

A

Alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Carmustine (Gliadel)
Lomustine (Ceenu)
Therapeutics

A

Brain tumors (cross blood-brain barrier)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Carmustine (Gliadel)
Lomustine (Ceenu)
Imp Side Effects

A

Renal toxicity, pulmonary fibrosis

21
Q

Carmustine (Gliadel)
Lomustine (Ceenu)
Other side effects

A

Profound myelosuppression,

severe nausea and vomiting

22
Q

Dacarbazine (DTIC)

class

23
Q

Dacarbazine (DTIC)

Mechanism

A

Alkylating agent; prodrug activated by liver

cytochromes

24
Q

Dacarbazine (DTIC)

Therapeutics

A

Part of ABVD for Hodgkin’s disease; also, malignant melanoma

25
Dacarbazine (DTIC) | "Other" Side Effects
Nausea and vomiting, myelosuppression (neutropenia, thrombocytopenia), flu-like symptoms (fever, fatigue)
26
Dacarbazine (DTIC) | Miscellaneous
IV administration
27
Procarbazine (Matulane) class
Triazenes
28
Procarbazine (Matulane) Mechanism
Alkylating agent; forms free radicals
29
Procarbazine (Matulane) Therapeutics
Hodgkin's lymphoma
30
Procarbazine (Matulane) Important side effects
May cause leukemia
31
Temozolomide (Temodar) class
Triazenes
32
Temozolomide (Temodar) Mechanism
Alkylating agent; nonenzymatic conversion | to methylhydrazine at physiologic pH
33
Temozolomide (Temodar) Therapeutics
Malignant gliomas
34
Temozolomide (Temodar) "Other" Side Effects
Nausea and vomiting, myelosuppression (neutropenia, thrombocytopenia), flu-like symptoms (fever, fatigue)
35
Temozolomide (Temodar) Miscellaneous
Taken orally
36
Cisplatin (Platinol) | class
Platinum analogs
37
Cisplatin (Platinol) | Mechanism
Alkylating agents that do not form carbonium ion intermediates or formally alkylate DNA; covalently bind nucleophilic sites on DNA (e.g., guanine N7); converted to active cytotoxic forms by reacting with water to form (+)charged, hydrated intermediates that react with DNA guanine, forming inter- and intrastand cross-links
38
Cisplatin (Platinol) | Therapeutics
Testicular, ovarian, cervical, and bladder cancers; also useful in treatment of head and neck cancer, and lung carcinoma
39
Cisplatin (Platinol) | Imp Side Effects
Nephrotoxicity, ototoxicity, peripheral motor and sensory neuropathy at high doses
40
Cisplatin (Platinol) | Other side effects
Severe nausea and vomiting, mild to moderate myelosuppression
41
Carboplatin (Paraplatin) Class
Platinum analogs
42
Carboplatin (Paraplatin) Mechanism
Alkylating agents that do not form carbonium ion intermediates or formally alkylate DNA; covalently bind nucleophilic sites on DNA (e.g., guanine N7); converted to active cytotoxic forms by reacting with water to form (+)charged, hydrated intermediates that react with DNA guanine, forming inter- and intrastand cross-links
43
Carboplatin (Paraplatin) Therapeutics
Ovarian cancer
44
Carboplatin (Paraplatin) Other side effects
Myelosuppression | thrombocytopenia
45
Oxaliplatin (Eloxatin) | class
Platinum analogs
46
Oxaliplatin (Eloxatin) | Mechanism
Alkylating agents that do not form carbonium ion intermediates or formally alkylate DNA; covalently bind nucleophilic sites on DNA (e.g., guanine N7); converted to active cytotoxic forms by reacting with water to form (+)charged, hydrated intermediates that react with DNA guanine, forming inter- and intrastand cross-links
47
Oxaliplatin (Eloxatin) | Therapeutics
Gastric and colorectal cancer
48
Oxaliplatin (Eloxatin) | Imp Side effects
Peripheral sensory neuropathy | cold-induced
49
Oxaliplatin (Eloxatin) | Other side effects
Neutropenia